PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-7.40%
Both companies show negative ROE. Martin Whitman would check if the entire market segment is distressed.
-6.83%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
-7.50%
Both companies show negative ROCE. Martin Whitman would investigate if external factors hamper profitability.
85.43%
Similar gross margin to TRAW's 94.64%. Walter Schloss would check if both companies have comparable cost structures.
-549.36%
Both companies are negative at the operating level. Martin Whitman would see if the entire niche faces fundamental challenges.
-541.91%
Both companies run at a net loss. Martin Whitman would see if broader market headwinds persist.